Roflumilast
Catalog #
27645-1
$185
*
●
●
Purchase
Description
Roflumilast is an orally active, selective inhibitor of phophodiesterase-4 (PDE-4) with IC50 value of 0.11 nM . Roflumilast displays anti-inflammatory and immunomodulatory in vitro.
This product has been cited 1 time.
●
Synonyms
Daxas; Daliresp; 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide
●
Product Data Gallery
Product Info
Storage and Usage
Citations1
Target(s)
PDE4
Formula
C17H14Cl2F2N2O3
MW
403.21 Da
CAS Registry #
162401-32-3
Background
The enzyme PDE-4 is found mainly in inflammatory cells, and Roflumilast acts as a selective, long-acting inhibitor of PDE-4. It has anti-inflammatory effects and is under development as an orally administered drug for the treatment of inflammatory conditions of the lungs such as asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). In vitro studies show that roflumilast inhibits the production of inflammatory mediators in a variety of human immune cells, suggesting a role for reducing COPD-related inflammation. Roflumilast is also found to decrease glucose levels in patients with newly diagnosed type-2 diabetes since diabetes is an important comorbidity associated with COPD.
References
Tashkin DP. Expert Opin Pharmacother. 2014 Jan;15(1):85-96.
Powered by Bioz
6405 Mira Mesa Blvd. Suite 100
San Diego, CA 92121
858-202-1401
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.